Skip to main content
. 2019 Sep 9;11:13–29. doi: 10.1016/j.ijpddr.2019.09.001

Table 2.

Sub-set of genes significantly (adjusted p values < 0.01) up-regulated greater than 2 fold, followed by their log2 fold change for C. elegans CB3474 ben-1(e1880)III exposed to 1.13 mM BZ for 4 h in response to all benzimidazoles tested.

Gene ID Putavie enzyme Gene description ABZ Δ log2 fold FBZ Δ log2 fold MBZ Δ log2 fold OxBZ Δ log2 fold TBZ Δ log2 fold
alh-5 Phase I Aldehyde dehydrogenase 2.25 1.64 1.25 1.28 1.74
dhs-23 Phase I DeHydrogenases, Short chain 3.28 3.76 2.82 8.20 3.90
E02C12.10 Phase I Uncharacterized oxidoreductase Dhs-27 7.20 12.83 6.38 15.47 8.33
C52A10.2 Phase I Carboxylic ester hydrolase 3.00 5.43 4.27 6.96 2.19
F13H6.3 Phase I Esterase CM06B1 2.35 2.15 2.74 4.07 1.27
gba-2 Phase I Putative glucosylceramidase 2 4.28 6.95 3.34 7.60 5.53
Y73C8C.10 Phase I FMN binding activity and oxidoreductase activity 5.73 5.54 4.48 7.40 5.83
T25G12.13 Phase I ortholoug of dhrs7b (dehydrogenase/reductase(SDR family) 5.91 7.07 5.09 9.62 7.20
T10B5.8 Phase I predicted FMN binding and oxidoreductase activity 2.96 1.95 1.62 5.33 4.16
cyp-13A6 Phase I CYtochrome P450 family 2.16 4.93 8.83 6.92 2.02
cyp-14A4 Phase I CYtochrome P450 family 2.26 3.03 3.47 8.14 1.78
cyp-34A9 Phase I CYtochrome P450 family 1.60 3.05 3.94 3.81 1.36
cyp-35A1 Phase I CYtochrome P450 family 8.61 7.53 6.79 9.63 6.06
cyp-35A2 Phase I CYtochrome P450 family 5.00 3.72 3.93 2.97 1.54
cyp-35A3 Phase I CYtochrome P450 family 6.06 7.44 4.97 8.25 7.61
cyp-35A4 Phase I CYtochrome P450 family 5.26 5.63 5.46 6.52 5.88
cyp-35A5 Phase I CYtochrome P450 family 7.11 6.40 5.88 7.10 7.67
cyp-35B2 Phase I CYtochrome P450 family 4.37 4.96 2.91 7.04 3.80
cyp-35C1 Phase I CYtochrome P450 family 7.18 5.45 5.61 5.55 3.24
ugt-8 Phase II UDP-GlucuronosylTransferase 5.26 3.91 3.42 5.69 4.73
ugt-9 Phase II UDP-GlucuronosylTransferase 4.32 4.53 3.56 6.90 4.54
ugt-14 Phase II UDP-GlucuronosylTransferase 3.41 2.52 2.56 4.29 2.26
ugt-25 Phase II UDP-glucuronosylTransferase 3.02 1.27 2.08 3.73 1.94
ugt-33 Phase II UDP-GlucuronosylTransferase 3.50 5.49 2.44 9.24 2.76
ugt-34 Phase II UDP-GlucuronosylTransferase 5.41 5.76 3.06 6.99 4.62
ugt-37 Phase II UDP-GlucuronosylTransferase 1.68 4.09 2.09 3.39 3.32
ugt-41 Phase II UDP-GlucuronosylTransferase 1.89 1.61 1.54 3.38 1.30
gst-5 Phase II Probable glutathione S-transferase 5 2.29 3.18 2.24 4.42 1.93
gst-21 Phase II Glutathione S-Transferase 1.73 2.08 1.35 5.89 2.15
C29F7.2 Phase II Predicted transferase, transfers phophorous-cantaining groups 4.10 4.09 2.87 4.07 2.25
H23N18.4 Phase II Predicted transferase, transfers hexosyl groups 5.83 7.02 4.19 7.33 7.16
nhr-142 Nuclear Hormone Receptor family 1.29 1.65 1.23 2.79 1.44
apy-1 Apyrase, guanosine and uridine-diphosphatase 1.17 1.47 1.85 2.67 1.19
cdr-1 CaDmium Responsive; Cadmium-inducible lysosomal protein CDR-1 4.26 5.24 8.76 8.19 10.37
irg-2 Infection Response protein 2.88 3.69 3.03 6.23 1.50
clec-206 C-type LECtin 6.47 5.70 5.91 7.44 6.43
ptr-22 PaTched Related family 5.16 4.37 3.66 4.75 3.99
F54B8.4 death domain binding activity; involved in innate immune response 1.62 1.33 1.52 2.56 1.53
vem-1 ortholog of PGRMC1; is involved in innate immune response 2.52 2.86 2.06 3.73 1.59
Y102A11A.9 Uncharacterized, up-regulated in response to chemicals 1.68 2.82 1.98 3.19 1.39
R09E12.9 Uncharacterized, up-regulated in response to chemicals 5.29 5.56 3.37 7.50 6.73